MX2023005430A - Formas estables de sal y cristal del 2-[3-({1-[2-(dimetilamino)eti l]-2-(2,2-dimetilpropil)-1h-1,3-benzodiazol-5-il}sulfonil)azetidi na-1-il]etan-1-ol. - Google Patents
Formas estables de sal y cristal del 2-[3-({1-[2-(dimetilamino)eti l]-2-(2,2-dimetilpropil)-1h-1,3-benzodiazol-5-il}sulfonil)azetidi na-1-il]etan-1-ol.Info
- Publication number
- MX2023005430A MX2023005430A MX2023005430A MX2023005430A MX2023005430A MX 2023005430 A MX2023005430 A MX 2023005430A MX 2023005430 A MX2023005430 A MX 2023005430A MX 2023005430 A MX2023005430 A MX 2023005430A MX 2023005430 A MX2023005430 A MX 2023005430A
- Authority
- MX
- Mexico
- Prior art keywords
- benzodiazol
- ethan
- dimethylpropyl
- sulfonyl
- dimethylamino
- Prior art date
Links
- 150000003839 salts Chemical group 0.000 title abstract 5
- 239000013078 crystal Chemical group 0.000 title abstract 3
- 229940126062 Compound A Drugs 0.000 abstract 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- OAYGNQGEUIFBFA-UHFFFAOYSA-N 2-[3-[1-[2-(dimethylamino)ethyl]-2-(2,2-dimethylpropyl)benzimidazol-5-yl]sulfonylazetidin-1-yl]ethanol Chemical compound C=1C=C2N(CCN(C)C)C(CC(C)(C)C)=NC2=CC=1S(=O)(=O)C1CN(CCO)C1 OAYGNQGEUIFBFA-UHFFFAOYSA-N 0.000 abstract 1
- 239000003556 cannabinoid 2 receptor agonist Substances 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
Abstract
Esta invención se refiere a nuevas sales y formas cristalinas de 2-[3-({1-[2-(dimetilamino)etil]-2-(2,2-dimetilpropil)-1H-1,3-benz odiazol-5-il}sulfonil)azetidin-1-il]etan-1-ol, abreviado simplemente como Compuesto A, el cual es un agonista selectivo del receptor CB2. La presente invención proporciona una sal del Compuesto A, una forma cristalina del mismo, un método para preparar dicha sal y una composición farmacéutica del mismo y su uso. Las sales del Compuesto A de la presente invención muestran buenas propiedades de formulación farmacéutica tales como alta solubilidad en agua, buena cristalinidad, alto punto de fusión, buena estabilidad química y física, o no delicuescencia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063112893P | 2020-11-12 | 2020-11-12 | |
PCT/JP2021/041552 WO2022102713A1 (en) | 2020-11-12 | 2021-11-11 | Stable salt and crystal forms of 2-[3-({1-[2-(dimethylamino)ethyl]-2-(2,2-dimethylpropyl)-1h-1,3-benzodiazol-5-yl}sulfonyl)azetidin-1-yl]ethan-1-ol |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023005430A true MX2023005430A (es) | 2023-11-14 |
Family
ID=81601223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023005430A MX2023005430A (es) | 2020-11-12 | 2021-11-11 | Formas estables de sal y cristal del 2-[3-({1-[2-(dimetilamino)eti l]-2-(2,2-dimetilpropil)-1h-1,3-benzodiazol-5-il}sulfonil)azetidi na-1-il]etan-1-ol. |
Country Status (12)
Country | Link |
---|---|
US (1) | US11964963B2 (es) |
EP (1) | EP4244220A1 (es) |
JP (1) | JP7427309B2 (es) |
KR (2) | KR102660003B1 (es) |
CN (2) | CN116322672B (es) |
AU (1) | AU2021380315B2 (es) |
BR (1) | BR122023023137A2 (es) |
CA (2) | CA3196706C (es) |
IL (1) | IL301333B1 (es) |
MX (1) | MX2023005430A (es) |
NZ (1) | NZ797451A (es) |
WO (1) | WO2022102713A1 (es) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2379533A4 (en) * | 2009-01-22 | 2012-07-04 | Raqualia Pharma Inc | N-SUBSTITUTED SATURATED HETEROCYCLIC SULFON COMPOUNDS WITH CB2 RECEPTOR AGONIST EFFECT |
-
2021
- 2021-11-11 NZ NZ797451A patent/NZ797451A/en unknown
- 2021-11-11 CA CA3196706A patent/CA3196706C/en active Active
- 2021-11-11 CN CN202180063678.2A patent/CN116322672B/zh active Active
- 2021-11-11 BR BR122023023137-6A patent/BR122023023137A2/pt not_active Application Discontinuation
- 2021-11-11 KR KR1020237017249A patent/KR102660003B1/ko active IP Right Grant
- 2021-11-11 US US18/035,195 patent/US11964963B2/en active Active
- 2021-11-11 EP EP21891958.7A patent/EP4244220A1/en active Pending
- 2021-11-11 KR KR1020247012064A patent/KR20240052885A/ko active Application Filing
- 2021-11-11 MX MX2023005430A patent/MX2023005430A/es unknown
- 2021-11-11 CA CA3238129A patent/CA3238129A1/en active Pending
- 2021-11-11 AU AU2021380315A patent/AU2021380315B2/en active Active
- 2021-11-11 JP JP2023528364A patent/JP7427309B2/ja active Active
- 2021-11-11 CN CN202410371199.2A patent/CN118561820A/zh active Pending
- 2021-11-11 IL IL301333A patent/IL301333B1/en unknown
- 2021-11-11 WO PCT/JP2021/041552 patent/WO2022102713A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN116322672A (zh) | 2023-06-23 |
KR20230093297A (ko) | 2023-06-27 |
EP4244220A1 (en) | 2023-09-20 |
CA3238129A1 (en) | 2022-05-19 |
BR112023003811A2 (pt) | 2023-03-28 |
KR102660003B1 (ko) | 2024-04-22 |
IL301333B1 (en) | 2024-09-01 |
JP2023544218A (ja) | 2023-10-20 |
CA3196706A1 (en) | 2022-05-19 |
US11964963B2 (en) | 2024-04-23 |
NZ797451A (en) | 2023-07-28 |
AU2021380315B2 (en) | 2023-04-13 |
CN118561820A (zh) | 2024-08-30 |
BR122023023137A2 (pt) | 2024-01-16 |
WO2022102713A1 (en) | 2022-05-19 |
IL301333A (en) | 2023-05-01 |
CA3196706C (en) | 2024-06-25 |
CN116322672B (zh) | 2024-04-09 |
US20230322737A1 (en) | 2023-10-12 |
JP7427309B2 (ja) | 2024-02-05 |
KR20240052885A (ko) | 2024-04-23 |
AU2021380315A1 (en) | 2023-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2332400C2 (ru) | Производные фенэтаноламина для лечения респираторных заболеваний | |
NL2000284C2 (nl) | Pyrazine-derivaten. | |
MX2022007105A (es) | Formas solidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-am ina de acido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1, 3] dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il) metil)-1h- benzo[d]imidazol-6-carboxilico. | |
KR101136251B1 (ko) | 구충제 | |
PE20060298A1 (es) | Derivados de acido carboxilico de bencimidazolona | |
EP1490342B8 (de) | Disubstituierte pyrazolylcarboxanilide | |
EA202091893A1 (ru) | Новые кристаллические формы | |
RU2012125372A (ru) | Производные пиразола в качестве ингибиторов 11-бета-hsd1 | |
NO20076498L (no) | Derivater av 4-(2-amino-1-hydroksyetyl)fenol som agonister av den betta2-adrenerge reseptoren | |
PE20001493A1 (es) | Derivados de acido pirazolcarboxilico, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
ATE411289T1 (de) | Indolalaninderivate als selektive s1p4-agonisten | |
PE20081545A1 (es) | Derivados de sulfonamida como inhibidores de acido graso sintasas | |
KR100462176B1 (ko) | 점착성수용체길항제 | |
PE20090813A1 (es) | Inhibidores de la 11b-hidroxiesteroide-deshidrogenasa | |
HUT53361A (en) | Process for producing 2-(1-piperazinyl)-4-phenyl cycloalkanopyridine derivatives and pharmaceutical compositions comprising such compounds as active ingredient | |
PE20080186A1 (es) | Derivados 4,6-disustituidos de 2-metoxi-6-etilamino-pirimidina como antagonistas del receptor de prostaglandina d2 | |
PE20081120A1 (es) | Derivados de hidantoina como inhibidores de metaloproteinasas de matriz (mmp) | |
NZ594641A (en) | Pyrazole derivatives used as ccr4 receptor antagonists | |
JP2013517273A5 (es) | ||
HRP20200606T1 (hr) | Derivati fenila kao agonisti kanabinoidnog receptora 2 | |
JP2020138979A (ja) | 眼科用組成物 | |
DK2059503T3 (en) | Aminopyrazole derivatives, processes for their preparation, and compositions containing these derivatives for the prevention or treatment of ischemic diseases | |
MX2023005430A (es) | Formas estables de sal y cristal del 2-[3-({1-[2-(dimetilamino)eti l]-2-(2,2-dimetilpropil)-1h-1,3-benzodiazol-5-il}sulfonil)azetidi na-1-il]etan-1-ol. | |
PE20040520A1 (es) | Derivados de n-acilamino bencil eter | |
RU2004137819A (ru) | Синтез диарилпиразолов |